Trial · NCT04816890
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body weight change from baseline to week 16 of treatment | From week 0 to week 16 | Change in body weight after 16 weeks of treatment |
| Secondary | TIR [70-180] mg/dL. | From week 0 to week 16 | Time In Range \[70-180\] mg/dL change from baseline to week 16 of treatment as measured by CGM. |
| Secondary | %TIR [70-180] mg/dL. | From week 0 to week 16 | Percentage of Time In Range \[70-180\] mg/dL change from baseline to week 16 of treatment as measured by CGM. |
| Secondary | TIR [70-140] mg/dL. | From week 0 to week 16 | Time In Range \[70-140\] mg/dL change from baseline to week 16 of treatment as measured by CGM. |
| Secondary | %TIR [70-140] mg/dL. | From week 0 to week 16 | Percentage of Time In Range \[70-140\] mg/dL change from baseline to week 16 of treatment as measured by CGM. |
| Secondary | MeanG_24h | From week 0 to week 16 | Average glucose over 24h change from baseline to week 16 of treatment |
| Secondary | CVG_24h | From week 0 to week 16 | Coefficient Of Variation of glucose over 24h change from baseline to week 16 of treatment. |
| Secondary | DistG_24h | From week 0 to week 16 | Distance travelled over 24h change from baseline to week 16 of treatment |
| Secondary | SDG_24h | From week 0 to week 16 | Standard Deviation of all glucose values over 24h change from baseline to week 16 of treatment |
| Secondary | HbA1c | From week 0 to week 16 | HbA1c change from baseline to week 16 of treatment |
| Secondary | Total Insulin doses | From week 0 to week 16 | Change from baseline of total insulin doses |
| Secondary | Prandial Insulin doses | From week 0 to week 16 | Change from baseline of prandial (per meal), insulin doses |
| Secondary | Basal Insulin doses | From week 0 to week 16 | Change from baseline of basal insulin doses |
| Secondary | Number of Adverse Events | From week 0 to week 16 | Number of Adverse Events observed during the treatment period |
| Secondary | Duration of Adverse Events | From week 0 to week 16 | Duration of Adverse Events observed during the treatment period |
| Secondary | Hypoglycaemic episodes | From week 0 to week 16 | Number of Hypoglycemic episodes during the 16 weeks treatment period |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04816890/registered